Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer
Kosteneffektivität von Datopotamab-Deruxtecan versus Chemotherapie als Erstlinienbehandlung bei Patient:innen mit fortgeschrittenem triple-negativem Brustkrebs
Frontiers in Pharmacology · 06.11.2026 · 17
DOI: 10.3389/fphar.2026.1965457 ↗Auf einen Blick
Eine Modellanalyse bewertete Datopotamab-Deruxtecan versus Chemotherapie bei fortgeschrittenem triple-negativem Brustkrebs. Unter den Modellannahmen war es in den USA und in China nicht kosteneffektiv.
Fragestellung
Wie kosteneffektiv ist Datopotamab-Deruxtecan im Vergleich zu Chemotherapie als Erstlinienbehandlung bei fortgeschrittenem triple-negativem Brustkrebs?
Methode
3-Zustands-Partitioned-Survival-Modell mit Daten aus TROPION-Breast02; Zeithorizont 10 Jahre, Zyklen 21 Tage; Perspektiven USA und China.
Ergebnisse
Gegenüber Chemotherapie stiegen die Kosten und QALYs in den USA um $565.572,29 bzw. 0,44; ICER $1.287.001,65/QALY. In China betrugen die Zunahmen $39.052,50 und 0,42 QALYs; ICER $92.640,82/QALY.
Einschränkungen
Ergebnisse waren empfindlich gegenüber Annahmen zur Behandlungsdauer.
Schlussfolgerung der Autor:innen
Bei den modellierten Preisen und Basisannahmen war Dato-DXd im Vergleich zu Chemotherapie in beiden Ländern nicht kosteneffektiv. Preisreduktionen könnten die Kosteneffektivität verbessern.
Kernaussagen
- USA: ICER $1.287.001,65/QALY
- China: ICER $92.640,82/QALY
- Ergebnisse abhängig von Annahmen zur Behandlungsdauer
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.11.2026. Verfasst von Zuojuan Xiang und 2 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The phase III TROPION-Breast02 trial demonstrated improved progression-free and overall survival with datopotamab deruxtecan (Dato-DXd) versus chemotherapy in patients with previously untreated advanced triple-negative breast cancer who were ineligible for immunotherapy. This study evaluated the cost-effectiveness of Dato-DXd from the perspectives of the United States (U.S.) and Chinese healthcare systems.
Methods
A three-state partitioned survival model was developed using TROPION-Breast02 data, with a 10-year horizon and 21-day cycles. Costs and utilities were obtained from public databases and published literature. The primary outcome was the incremental cost-effectiveness ratio (ICER), expressed as cost per quality-adjusted life-year (QALY) gained. Willingness-to-pay thresholds were $150,000/QALY in the U.S. and $27,906/QALY in China. Sensitivity and scenario analyses assessed uncertainty and the robustness of the findings, and exploratory subgroup analyses were performed.
Results
Compared with chemotherapy, Dato-DXd increased costs by $565,572.29 and QALYs by 0.44 in the U.S., yielding an ICER of $1,287,001.65/QALY. In China, the corresponding increases were $39,052.50 and 0.42 QALYs, yielding an ICER of $92,640.82/QALY. Price reductions of approximately 62.43% in the U.S. and 28.83% in China were required to reach the respective cost-effectiveness thresholds. Progression-free survival utility and Dato-DXd price were the most influential parameters in one-way sensitivity analyses. In exploratory scenario analyses, limiting treatment duration to the reported median yielded cost-effective results in both countries. Assuming unchanged efficacy, a hypothetical reduction in the Dato-DXd dose from 6 to 4 mg/kg made it cost-effective in China but not in the U.S. Exploratory subgroup analyses yielded conclusions consistent with the base-case findings.
Conclusion
At the modeled prices and under the base-case assumptions, Dato-DXd was not cost-effective compared with chemotherapy in either country. Price reductions could improve its cost-effectiveness. Results were sensitive to assumptions about treatment duration. The potential economic benefits of reduced-dose or fixed-duration strategies depend on clinical confirmation of maintained efficacy and acceptable safety.
Zitieren
APA
Xiang, Z., Xia, Q., & Li, Z. (2026). Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1965457
Vancouver
Xiang Z, Xia Q, Li Z. Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1965457
BibTeX
@article{Xiang2026,
author = {Xiang, Zuojuan and Xia, Qiao and Li, Zhengxiong},
title = {Cost-effectiveness of datopotamab deruxtecan versus chemotherapy as a first-line treatment for patients with advanced triple-negative breast cancer},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1965457}
}
EUVIMED